STAT+: A controversial drug for premature births, which FDA wants withdrawn, is tied to elevated cancer risk

The key ingredient in a controversial medicine used to prevent premature births is associated with a higher risk of cancer in people that were exposed to the treatment in utero, according to a new study.

Specifically, those exposed to 17-OHPC had nearly double the risk of any cancer compared to those not exposed, although the risk appeared to vary depending on the cancer. For instance, children exposed to 17-OHPC had more than 34 times greater risk of brain cancer, and as adults had more than five times greater risk of colorectal and prostate cancers.

Continue to STAT+ to read the full story…